CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study
evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory
lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic
visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12.
Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with
either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.